From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Latest Views & News

Whilst I wait for GlaxoSmithKline to split itself…more on the UK housing market via Barratt Developments

By Chris Bailey | Wednesday 9 February 2022


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I am looking forward to the GlaxoSmithKline (GSK) conference call later today. Whilst technically it is focused on the full year 2021 numbers out earlier today (which showed rising sales and falling profits), far more important is the confirmation that it is ‘on track to demerge a new world-leading Consumer Healthcare business mid-2022’. Last month I was amused by the (ultimately unsuccessful) partial bid approach by Unilever (ULVR) but my instinct is that the Pharmaceutical / Vaccines business is still underappreciated going forward. I was certainly pleased to see the ‘pipeline of 21 vaccines and 43 medicines’ angles and I do wonder – when the business split occurs in a few months time – whether not only retaining but adding to this part of the business. Something to be more thoughtful about later this year whilst, despite the excellent total return performance over the last year, I remain a strong HOLDer. So whilst I continue to hang onto my GlaxoSmithKline shares…what do I make of today’s interim results announcement from FTSE 100 housebuilder Barratt Developments (BDEV)?…

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Friday »

TERN

Tern – Is There More Bad News On The Way?

Thursday »

ZYT

Zytronic – now a recovery Buy?

 

YGEN

Buy Yourgene - target 0.6p

 

ROO

Keep avoiding Deliveroo shares

Friday »

THS

Tharisa – Q1 report, still a value Buy

 

SBRY

Sainsbury’s has a good Christmas

 

UJO

Union Jack Oil - you were warned!